Across the whole pharma sector, there are four or five stocks big one out there which are going to gain market share. So, CDMO is one space within pharma which should do well as we go along. But pharma as a whole space per se has been doing okay and we continue to believe that incrementally also pharma should continue to do well in the coming year also.
Swiggy shares fall 2%, down for 3rd session, as MSCI set to remove stock from Global Standard Indexes from September 7
Shares of Swiggy experienced a decline following MSCI’s decision to exclude the company from global indexes, prompted by its shift to full Indian ownership and
September 3, 2026